Minimal residual disease testing could transform cancer care—personalized therapies, early relapse detection, and improved ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all ...

Guardant Health's heavy investment in R&D, growing from $10.9 million in 2016 to $365.1 million in 2023, indicates a focus on future growth. Learn more on GH stock here.

Cancer Risk Linked to P53 in Ulcerative Colitis Oct. 25, 2024 — Researchers have elucidated the role of the p53 gene in ulcerative ... Colon Cancer Screening Test Reduces Risk of Colorectal ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

Beyond imaging, AI is also making strides in analyzing genetic data to identify cancer risks at a molecular level. Cancer is ...

PanCAN has funded a project known as REGENERATE, which focuses on genetic education and genetic testing for people at risk for pancreatic cancer ... liquid biopsies are a hot topic in cancer biology ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.